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and the ITalian Excluder Registry (ITER) Investigators, Florence and Varese, Italy
Background: To report the midterm results of elective endovascular aortic repair (EVAR) of abdominal aortic aneurysms
(AAAs) in a multicenter, clinical unsponsored registry using the Gore Excluder endograft.
Methods: This study is a retrospective analysis of a multicenter, prospective registry that involved nine centers in Italy.
Periodic clinical and radiographic follow-up with computed tomography scans were performed at 1, 6, and 12 months
after the procedure, and on a yearly basis thereafter.
Results: A total of 872 patients underwent elective EVAR. Primary technical success was 97.5%, and hospital mortality was
1.0% (9/872). At least 816 (93.6%) patients underwent a follow-up control. Freedom from all-cause death was estimated
to be 97.9% at 1 year, 93.4% at 3 years, and 88.5% at 5 years. Aneurysm-related mortality was 1.6% (n [ 13) with only
two late AAA-related deaths observed at 21 and 36 months. Signiﬁcant predictors of all-cause mortality included age
(P < .001) and AAA maximum diameter (P[ .027). Overall conversion rate was 2.3% (n[ 19). Mean elapsed time from
initial intervention to surgical conversion was 23 6 18 months (range, 0-52 months). Late rupture was detected in four
(0.5%) cases: two of these patients died after conversion. The rate of any reintervention was 9.4% (n[ 77); most of them
were required within the ﬁrst 24 months. The leading cause of reintervention was endoleak (n [ 41; 5.0%). Limb
thrombosis occurred in nine (1.1%) cases. Freedom from reintervention at 1, 3, and 5 years of follow-up were 98.6%,
94.6%, and 86.5%.
Conclusions: The ITalian Gore Excluder Registry is the largest clinical unsponsored registry using a single device, with the
longest follow-up period so far. The present experience conﬁrms the effectiveness of EVAR using the Gore Excluder with
low rates of mortality, migration, reintervention, and limb thrombosis. (J Vasc Surg 2014;59:52-7.)During the last two decades, endovascular aortic repair
(EVAR) gained popularity for abdominal aortic aneurysm
(AAA) repair.1,2 There is no longer debate about the early
beneﬁts of EVAR, including shorter hospital stays, less
blood loss, shorter operating times, and lower early
morbidity and mortality.3,4 In contrast, randomized clinical
trials have raised concerns about late outcomes of EVAR,
including complications, loss of survival beneﬁt, and need
for reinterventions.5,6 The design and conduct of these
trials may not reﬂect “real-world” practice, so the
outcomes may not be applicable to the general population.
In contrast, registries report more realistic results as they
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Concomitant with the increased EVAR utilization
has been the availability of a variety of endograft (EG)
designs and conﬁgurations to treat AAAs, each of them
evaluated in pivotal studies against primary endovascular
outcomes.7-9
The aim of this report is to present the 3-year follow-up
results of an Italian multicenter registry (ITER, ITalian
Excluder Registry) using the Gore Excluder EG.
METHODS
This report describes the results of a multicenter,
prospective registry of EVAR for infrarenal AAA using
the Gore Excluder (W. L. Gore & Associates Inc, Flagstaff,
Ariz) bifurcated EG. The registry was a single device
registry of elective EVAR that involved nine centers in Italy
(participating investigators are listed in the Appendix,
online only). All the centers had experience of at least 40
cases with this type of EG. Generally, indication for AAA
treatment with this device included:
d An intact AAA diameter of $50 mm, or any aneurysm
with an increase of $5 mm in two consecutive diag-
nostic evaluations, symptoms, or radiologic ﬁndings
of impeding rupture;
d Patent, adequate femoral-iliac access vessels to accept
introducer sheaths of 18 F for the main body and
12 F for the contralateral iliac extension;
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 1 Pratesi et al 53d An infrarenal aortic neck diameter range of 19 to
29 mm and a minimum aortic neck length of 15 mm;
d A proximal aortic neck angulation #60;
d Iliac artery treatment diameter range of 8 to 18.5 mm
and iliac distal vessel seal zone length of at least 10 mm.
Patient management. Preoperative investigation con-
sisted of spiral/computed tomography (CT) angiography
scans, whereas operative risk assessment was stratiﬁed
accordingly to the classiﬁcation of the American Society of
Anesthesiologists.10 In all centers, EVAR was performed
in an operating room equipped with endovascular capabil-
ities, meaning the availability of a mobile C-arm, an auto-
matic injector, and a wide inventory of EGs. The time period
included two different versions of the Gore Excluder: the
original device and the enhanced EG, that with the new
polytetraﬂuoroethylene microstructure redesigned to re-
duce porosity and ﬂuid transmigration. Clinical and radio-
graphic follow-upwithCT scans were performed at 1, 6, and
12 months after the procedure, and on a yearly basis
thereafter. Angiography, Doppler ultrasound, and plain
X rays were performed in selected cases. Endoleaks or
enlargement correction (regardless of endoleak status) were
intensively studied and considered for reintervention or
conversion to conventional repair. This consideration
included the local principal investigator’s and attending
physician’s assessment of an individual subject’s comorbid-
ities, life expectancy, and the subject’s personal choices.
Deﬁnition and outcomes. Comorbidities and risk
score were deﬁned prospectively accordingly to the guide-
lines of the Society for Vascular Surgery/American Associa-
tion for Vascular Surgery.11,12 Technical success was deﬁned
as no type I or III endoleak at the conclusion of the proce-
dure; further primary end points were operative (<30 days)
mortality, aneurysm rupture, aneurysm-related mortality,
conversion to open repair, reintervention, and device-
related adverse events (migration, thrombosis, or kinking).
Changes of $5 mm in the minor axis were considered
signiﬁcant for either enlargement or shrinkage.
Statistical analysis. All clinical and procedural data
were prospectively collected and recorded into a computer-
ized database registry. Extracted database variables were
tabulated using Microsoft Excel (Microsoft Corp, Red-
mond, Wash), and statistical analysis was computed using
SAS Version 9.2 (SAS Institute, Cary, NC). Life-table esti-
mates were provided for mortality and reintervention.
Results are expressed as mean 6 standard deviation for
continuous variables and frequencies for the categorical
ones. A P value less than .05 was considered statistically
signiﬁcant. Formal cost analysis was not performed; as well,
we did not perform comparison between the original device
and the enhanced EG, that with the new polytetraﬂuoro-
ethylene microstructure redesigned to reduce porosity and
ﬂuid transmigration.
RESULTS
Between October 1998 and December 2006, a total of
872 patients underwent elective EVAR and were enrolledinto the registry. We treated 802 (91.9%) males; mean
age was 72.7 6 8.5 years (range, 52-95 years). Comorbid-
ities are listed in Table I: cardiovascular risk factors were
present in the majority of patients, and most (n ¼ 517;
59.3%) had a high operative risk (American Society of
Anesthesiologists scale III-IV). Main AAA features are
depicted in Table II: a neck length of <15 mm was present
in 82 (9.5%) patients. Mean angle of the proximal aortic
neck was 26.2 6 15.1 degrees (range, 0-75 degrees).
The original permeability device was used in 656 (75.2%)
patients, and the low permeability device in 216 (24.8%).
Perioperative outcomes. Primary technical success
was achieved in 850 (97.5%) patients. Regional anesthesia
was utilized in 462 (52.9%) patients, general anesthesia
in 275 (31.5%), and local anesthesia with sedation
in 135 (15.6%). Total percutaneous intervention was
never performed. Mean procedure time was 113 6 83
minutes (range, 30-480 minutes), with a mean ﬂuoroscopic
time of 26 6 14 minutes. Contrast agent averaged
144 6 104 mL. Blood loss averaged 234 mL (range,
0-3000 mL). Length of hospitalization was 6 days (median,
4 days). Operative mortality was 1.0% (9/872). The most
frequent complication involved access vessels (n ¼ 11;
1.3%). EG-related complications were observed in four
(0.4%) cases: kinking of an iliac limb (n ¼ 3; 0.3%) was
treated with additional percutaneous transluminal angio-
plasty (PTA) stent, andmigration (n¼ 1; 0.1%). Conversion
to open repair was performed in three (0.3%) cases for per-
sisting type I endoleak (n ¼ 2), and the previously
mentioned migration (n ¼ 1).
Follow-up and survival. As of December 2009, at
least 816 (93.6%) patients underwent one follow-up visit
and CT scan. All-cause mortality was 8.7% (n ¼ 71): most
late deaths were caused by cardiovascular events (n ¼ 13,
mainly acute coronary syndrome). Freedom from all-cause
death was 97.9% at 1 year, 93.4% at 3 years, and 88.5% at
5 years (Fig 1). Signiﬁcant predictors of all-cause mortality
included age (P < .001) and AAA maximum diameter
(P ¼ .027). Aneurysm-related mortality was 1.6% (n ¼ 13).
Most (11/13) AAA-related deaths occurred within the
initial hospital admission and included: cardiovascular
events (n ¼ 5), multiple organ failure (n ¼ 2), acute kidney
injury (n ¼ 2), and pulmonary complications (n ¼ 2).
Subsequent AAA-related deaths were observed in two
cases only, at 21 and 36 months. Estimated freedom from
AAA-related death was 98.5% at 1 year, 98.3% at 3 years,
and 97.9% at 5 years (Fig 2).
Aneurysm rupture. Postoperative ruptures (n ¼ 4)
occurred between 1 and 20 months. An endoleak was
detected in all the cases (type I, n ¼ 3; type II, n ¼ 1).
Urgent conversion with the EG explantation and graft
replacement was performed in all the cases. Two of the
four patients died either of the rupture itself or subsequent
complications thereof.
Conversion to open surgical repair. Overall conver-
sion rate was 2.3% (n ¼ 19). The indication for conversion
to open surgical repair included endoleak with sac enlarge-
ment (n ¼ 14) or persistent endoleak and/or migration,
Table II. Morphology and sizing of the abdominal
aortic aneurysms (AAAs)
Parameter Size, mm
AAA diameter 52.4 6 3.0
#50 mm 44 (5.0)
Proximal neck diameter 27 6 12
Proximal neck length 26 6 13
#15 mm 83 (9.5)
Neck a-angle,  26 6 15
Right common iliac diameter 13.7 6 9.9
Left common iliac diameter 12.9 6 9.1
SD, Standard deviation.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
Fig 1. Freedom from all-cause death.
Table I. Comorbidities and risk factors of the population
No. (%)
Demographics
Age, years 72.7 6 8.5
Males 802 (91.9)
Comorbidities
Hypertension 625 (71.7)
Chronic obstructive pulmonary disease 467 (53.6)
Coronary artery disease 428 (49.1)
History of smoking 420 (48.1)
Dyslipidemia 339 (38.8)
Hostile abdomen 300 (34.4)
Cerebrovascular disease 173 (19.8)
Peripheral arterial disease 164 (18.8)
Diabetes 128 (14.7)
Renal dysfunction 100 (11.5)
Operative proﬁle
ASA I-II 355 (40.7)
ASA III-IV 517 (59.3)
ASA, American Society of Anesthesiologists; SD, standard deviation.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
Fig 2. Freedom from abdominal aortic aneurysm (AAA)-related
death.
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Three (0.3%) conversions occurred at the indexed interven-
tion: the mean elapsed time from initial implantation to
surgical conversion was 23.2 6 18 months (range, 0-
52 months). Predictors for conversion were not identiﬁed.
Reintervention. During the follow-up, a total of 79
reinterventions were performed in 74 patients, resulting in
a 9.7% incidence of any reintervention. The mean interval
from the indexed intervention was 20 months, but most
(n ¼ 55; 71.4%) were performed within 24 months.
Endoleak (n ¼ 41; 5.0%) was the leading cause for reinter-
vention, followed by limb thrombosis (n ¼ 9; 1.1%). EG
migration occurred in four cases. Reintervention was
catheter-based in 50 (63.2%) cases and included proximal or
distal extension (n¼ 26; 52%), embolization (n¼ 20; 40%),
and PTA (n ¼ 4; 8.0%). Open procedures included
conventional aortic graft replacement (n ¼ 19), graft limb
thrombectomy (n ¼ 3), extra-anatomic bypass for limb
occlusion (n¼ 3), iliac-femoral bypass (n¼ 2), laparoscopic
ligation of the inferior mesenteric artery (n ¼ 1), and repair
of common femoral artery pseudoaneurysm (n ¼ 1).Freedom from reintervention at 1, 3, and 5 years of follow-
up were 98.6%, 94.6%, and 86.5% respectively (Fig 3).
Predictors for reintervention were not identiﬁed.
Limb thrombosis. There were nine (1.1%) graft limb
thrombosis at a mean 20.6 months (range, 6-48 months).
Five occurred in the ﬁrst 12 months. Three were treated
with a femoro-femoral by-pass, three with thrombec-
tomy, and the remaining three using thrombolysis and
additional PTA stenting.
Endoleak. Endoleaks at each intervals of follow-up are
represented in Table III. At 1-year follow-up, the aneurysm
sac was stable or decreased in 94.8% (635/670) of the
cases, whereas enlargement was noted in 5.2% (n ¼ 35) of
patients. Estimated freedom from endoleak was 82.5% at
1 year, 75.8% at 3 years, and 71.5% at 5 years (Fig 4). The
maximum AAA diameter (P ¼ .007) was a signiﬁcant
predictor of sac enlargement.
DISCUSSION
ITER is the largest prospective, unfunded clinical
registry of elective EVAR using a single device. The most
Fig 3. Freedom from reintervention.
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migration, reintervention, and iliac limb thrombosis with
the use of the Gore Excluder.
Few registries have been published in literature report-
ing the outcomes of a single device; even more importantly,
mid- to long-term follow-up has not been consistently re-
ported.13,14 Other registries have enrolled hundreds of
patients, but results were reported in the range of 30 days
to 6 months only. The most consistent registry available at
this time is Talent Unidoc Retrospective Italian Study
(TAURIS),15 a multicenter study that involved 10 centers
in Italy. It recruited 557 patients overall with a mean
follow-up of 25 months, and 349 were available with a CT
control at 12 months. Considering these data, at this
moment, ITER is the largest registry available, including
670 patients with a CT scan at 1-year and a follow-up
mean of 28 months. Our registry compares well with the
results of the combined IDE cohort of the Gore Excluder
that included 565 patients overall: we can conﬁrm the low
complications rate using this EG either in the early or in
the midterm follow-up.8 The most important difference
with that cohort is the 3-year survival of 93.4% rather than
the 82% reported in the IDE. This unanticipated data could
be explained by the different age at treatment and the better
operative risk proﬁle of our patients. Despite these signiﬁ-
cant differences, we had similar satisfactory results when
considering the primary outcomes such as open conversion,
AAA secondary ruptures, migration, and EG-related
complications.
Through the last decade, Gore Excluder implantation
showed a high success rate: Bush et al16 reported an 89%
primary technical success rate. This is probably the lowest re-
ported rate, but it refers to the early experiencewith the orig-
inal permeability device. More recently, Ghotbi et al17
reported full success in the ﬁrst 100 cases of their single-
center experience. Some authors tested different EGs in
device-speciﬁc outcome analysis, including the Gore
Excluder: Pulli and coworkers18 achieved a 98% success
rate with no increased need of adjunctive procedures and
no intraoperative migration with the Gore Excluder.Actually, our study compares well with these data and could
have been even better: the 97.5% we reported in this registry
could have been a full success because an intraoperative
migrationoccurred for a technical inaccuracy, a complication
that, although typical of the long run, has remained very low
at the 3-year analysis (sustaining <1%). These data are sup-
ported by the results of the EUROpean collaborators on
Stent-graft Techniques for abdominal aortic Aneurysm
Repair (EUROSTAR) registry.19 In that analysis, despite
the Gore Excluder being the second most utilized EG, as
well as the most frequently utilized in more hostile anato-
mies, it had the lowest rate of migration: these results
conﬁrmed the safety and effectiveness of the device.
Since its advent, the primary aim of EVAR has been
considered the prevention of rupture. In this sense, two
randomized clinical trials raised concerns about the long-
term safety of EVAR because most of the reported late
deaths have been ascribed to secondary rupture.20
However, it should be said that most of these ruptures
should have been charged to use of early-generation EGs
and might have been averted by an appropriate reinterven-
tion at an appropriate interval. Our results can support the
safety of EVAR in daily practice: the 1.6% AAA-related
death experienced in our registry is similar to the 1.6% to
1.8% range reported in several single-center data, as well
as the 1.9% rate in the EUROSTAR registry.19 This does
not mean that we should minimize the problem, partly
because the mortality after secondary rupture remains
considerable despite prompt diagnosis, as occurred in our
experience.3,8,9
Preventing rupture has been intended the real rationale
of EVAR, but the prevention of secondary intervention
with particular attention to open conversion is no less
important.18,21 The incidence of secondary procedures
was commonly reported in the 10% to 15% range.18,19,22-24
In particular, among the different devices included in the
EUROSTAR registry,19 the Gore Excluder annual
freedom from reintervention rate was the lowest at 3.5%.
A low reintervention rate is important not only for the
patients, but also for the overall safety and cost-
effectiveness of the procedure. The freedom from reinter-
vention at 5 years was 86.5% in our registry; that is
favorable if compared with previous analyses ranging
from 65% to 82% at 5 years.18,22,24,25 Equally important,
we had no adjunctive mortality after secondary procedures.
In reference to these same studies, the fact that we were
not able to replicate the data in which a large AAA diam-
eter is a predictor for reintervention deserves a comment.
In fact, a larger diameter has been more frequently associ-
ated with EVAR treatment outside the instructions for use
in these studies.22,24 Our unexpected ﬁnding could be
a further signiﬁcant aspect to attest the reliability of the
registry data and one that conﬁrms the homogeneous
adherence to the inclusion criteria.
Previous reports have also raised concerns about limb
thrombosis, and implicated it in being a leading cause of
secondary interventions.19,22,25-27 No speciﬁc device-
related analysis has been performed so far. In our registry,
Table III. Summary of endoleaks by period
Subjects
assessed
Follow-up period
1 month
(n = 863),
No. (%)
12 months
(n = 670),
No. (%)
24 months
(n = 482),
No. (%)
36 months
(n = 394),
No. (%)
48 months
(n = 257),
No. (%)
60 months
(n = 160),
No. (%)
Any endoleak 94 (10.9) 78 (11.7) 54 (11.3) 41 (10.5) 20 (7.8) 4 (2.5)
Type I 14 (1.6) 7 (1.1) 4 (0.9) 3 (0.7) 0 (0.0) 0 (0.0)
Type II 67 (7.8) 61 (9.1) 46 (9.5) 27 (6.9) 15 (6.0) 0 (0.0)
Type III 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Unknown 13 (1.5) 10 (1.5) 4 (0.9) 10 (2.6) 5 (1.8) 4 (2.5)
No endoleak 769 (89.1) 592 (88.3) 428 (88.8) 353 (89.6) 237 (92.4) 156 (97.5)
Fig 4. Freedom from all types of endoleak.
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36 months: of note, this is an aspect that was not reported
in detail in the IDE cohort, and ﬁnds support in previous
experiences. In their device-speciﬁc outcome analysis
involving four different EGs, Pulli and coworkers18 re-
ported the lowest limb thrombosis rate using the Gore
Excluder. In a similar study, Abruzzese et al22 performed
an anatomically stratiﬁed device-speciﬁc analysis to evaluate
the performance of three different EGs. Despite the Gore
Excluder being implanted more frequently in women,
more frequently outside the indications for use, it had
the lowest limb thrombosis rate with no difference in terms
of migrations or disconnections.22
Another important ﬁnding that testiﬁes to the reli-
ability of our registry data is the conﬁrmation of age as
a predictor of postoperative survival.28-31 In a review of
their ﬁrst decade of EVAR, Brewster et al23 conﬁrmed
that age was an independent predictor of survival especially
in the long run; since they had good long-term overall
outcomes with EVAR, they suggested it could be used as
a reasonable alternative to conventional open repair in
a broad range of patients with suitable anatomy, including
younger and lower risk individuals. We had similar ﬁndings:
these should not be considered a deﬁnitive statement, but
the concept of this study outlines that the association of
a suitable anatomy and a good perioperative risk proﬁlecould have positively inﬂuenced either technical or clinical
outcomes in our registry cohort.8 Also, the diameter of the
AAAs have been identiﬁed as an independent risk factor for
long-term outcomes. Zarins et al32 showed that patients
with large aneurysms ($6 cm) were older and more likely
to need a secondary procedure during the 5-year follow-up
period, and comparison of the Kaplan-Meier curves
showed that they had a signiﬁcantly shorter life expectancy
than those with smaller AAAs. Lomazzi et al29 evaluated
a large cohort of EVAR patients and identiﬁed that AAA
diameter was one of the most important variables to predict
decreased survival. Our study is not different: diameter was
a predictor of endoleak and survival in the long run, and
several papers already published supported our data.
There are some limitations in the present study.
Mainly, our study design is retrospective; although data
were prospectively collected, they certainly include poten-
tial confounding variables such as selection bias and data
collection. However, similar design is present in other
studies, and our results are in consonance with them;
although the incidence of complications and mortality
related to the AAA could be higher due to the number
of patients lost to follow-up.
CONCLUSIONS
The ITER is the largest clinical unsponsored registry
using a single device, with the longest follow-up period so far.
The present experience conﬁrms the near-term effec-
tiveness of EVAR using the Gore Excluder with low
mortality rate, as well as the 3-year high rate of technical
success and the low rate of EG-related complication.
At an interim 3-year analysis, EVAR with the Gore
Excluder is conﬁrmed to have a low migration rate, a low
reintervention rate, and a low limb thrombosis rate.
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